医药制造业

Search documents
东富龙申请用于微流体混合的单级混合器及多级混合器专利,提高了两相液体的混合效果
Jin Rong Jie· 2025-06-14 10:07
Core Viewpoint - Dongfulong Life Science Technology Co., Ltd. has applied for a patent for a single-stage and multi-stage mixer for microfluidic mixing, indicating its focus on innovation in pharmaceutical engineering technology [1] Company Overview - Dongfulong Life Science Technology Co., Ltd. was established in 2015 in Shanghai, primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 100 million RMB [2] - Dongfulong Technology Group Co., Ltd. was founded in 1993 in Shanghai, focusing on specialized equipment manufacturing, with a registered capital of approximately 765.83 million RMB [2] Patent Details - The patent application, published as CN120132922A, was filed on December 2023 and pertains to a microfluidic mixer designed to enhance the mixing effect of two-phase liquids and improve the quality of nanoparticle formation [1] - The mixer includes a diversion section, a convergence section, and at least one liquid level conversion section, which allows for the alteration of the boundary order of liquids to facilitate better mixing [1]
南通立洋化学等申请一种 2-氰基吡啶的纯化方法专利 能将 2-氰基吡啶提纯至 99.99%
Jin Rong Jie· 2025-06-14 07:05
金融界 2025 年 6 月 14 日消息,国家知识产权局信息显示,南通立洋化学有限公司;南通醋酸化工股份 有限公司申请一项名为"一种 2-氰基吡啶的纯化方法"的专利,公开号 CN120136782A,申请日期为 2023 年 12 月。 南通醋酸化工股份有限公司,成立于1959年,位于南通市,是一家以从事化学原料和化学制品制造业为 主的企业。企业注册资本20738.1万人民币。通过天眼查大数据分析,南通醋酸化工股份有限公司共对 外投资了15家企业,参与招投标项目13次,财产线索方面有商标信息6条,专利信息173条,此外企业还 拥有行政许可25个。 专利摘要显示,本发明公开了一种 2‑氰基吡啶的纯化方法,属于化工技术领域。本发明 2‑氰基吡啶的 纯化方法包括:在以 2‑甲基吡啶为原料,氨氧催化制备 2‑氰基吡啶粗品过程中,将得到的 2‑氰基吡啶 粗品经过装有金属吸附剂的吸附柱进行吸附除杂,即得到纯品 2‑氰基吡啶;所述金属吸附剂为 Li、 Cs、Be、Rb 中的两种或多种金属与石墨烯复合而成。通过该方法能够将纯度为 99.8%的 2‑氰基吡啶提 纯至 99.99%,得到高品质的 2‑氰基吡啶,同时无需回流回流 ...
*ST景峰: 关于2024年年报问询函回复的公告
Zheng Quan Zhi Xing· 2025-06-12 12:19
Core Viewpoint - Hunan Jingfeng Pharmaceutical Co., Ltd. has received a debt waiver from nine bondholders, which significantly impacts its financial structure and ongoing restructuring efforts [1][2][3] Debt Waiver Details - The company has entered into a debt waiver agreement with nine bondholders, which includes a total waiver of 1.1 billion yuan in principal and all accrued interest and penalties, amounting to a total of 2.66 billion yuan [20][21] - The debt waiver is unconditional, irrevocable, and does not require any further internal approval processes [6][13][21] Financial Position - As of the waiver date, the company had outstanding debts of 294.64 million yuan in principal, 93.64 million yuan in interest, and 62.62 million yuan in penalties [6][7] - Following the debt waiver, the remaining debts will be 184.64 million yuan in principal, with no remaining interest or penalties [6][7] Fund Management and Relationships - The nine bondholders are managed by five fund management companies, which have confirmed that they have no relationships with the company, its controlling shareholders, or its executives [4][5][12] - The fund management companies have followed proper internal decision-making procedures regarding the debt waiver [5][12] Restructuring Process - The company is currently in a pre-restructuring phase, with the debt waiver not being a prerequisite for the restructuring process [13][20] - The restructuring efforts have led to a positive shift in the company's net assets, moving from negative to positive [20][22] Asset Management - The company has sold a low-efficiency asset, "Taihu Star," for 64.69 million yuan, which has improved its cash flow and reduced operational pressure [20][21] - The asset sale and debt waiver are part of a broader strategy to optimize the company's financial structure and improve operational capabilities [20][22]
宏源药业(301246) - 2025年06月12日投资者关系活动记录表
2025-06-12 11:05
Financial Performance - The company's revenue and net profit are expected to show growth in Q2 2025 compared to Q1 2025, with current order volumes meeting expectations [1] - Direct exports to the U.S. account for a low percentage of revenue, minimizing the impact of recent U.S. tariffs [1] - The company has faced a significant decline in net profit since its IPO, with the stock price currently less than one-third of the initial offering price of 50 CNY per share [2][3] Market Challenges - The stock price has been in a long-term decline, attributed to macroeconomic factors, market conditions, and industry developments [2][3] - The company’s internal value does not align with its market capitalization, facing issues such as insufficient information disclosure and a lack of recognized business logic [3] Product Development - The solid-state battery project has completed kilogram-level experiments and is currently in the process optimization phase, with no mass production yet [2][4] - The company is focusing on high-end raw materials and specialty intermediates in the pharmaceutical sector, aiming to expand its international market presence [4] Strategic Initiatives - The company plans to enhance its core competitiveness through improved main business operations and effective value communication to investors [2][3] - In the lithium battery materials sector, the company aims to reduce production costs through technological upgrades and expansion into upstream supply chains [4]
浩欧博:公司市盈率显著高于行业市盈率水平
news flash· 2025-06-12 10:10
浩欧博发布异动公告,公司股票交易连续3个交易日内收盘价格涨幅偏离值累计达到30%,属于股票交 易异常波动情形。经公司自查并向控股股东、实际控制人核实,不存在应披露而未披露的重大信息。截 至2025年6月12日,公司收盘价为137.88元/股,最新市盈率为236.24倍,滚动市盈率为251.04倍,医药 制造业最近一个月平均滚动市盈率为28.07倍。公司特别提醒广大投资者,注意投资风险,理性决策, 审慎投资。 ...
晚间公告丨6月12日这些公告有看头
Di Yi Cai Jing· 2025-06-12 10:07
Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen markets have released important announcements, providing insights for investors [1] Company Announcements - JingJin Equipment's actual controller, chairman, and general manager has been detained and is under investigation, but the company's operations remain normal and unaffected [3] - XinBeiYang reported that its stock price has deviated significantly, but confirmed that its operations and external environment have not changed materially [4] - Jiuqi Co. announced a share transfer price of 14.62 yuan per share, with 2,330,880 shares fully subscribed by seven institutional investors [5] - Yuanlong Yatu confirmed that there are no undisclosed significant matters affecting its operations despite stock price fluctuations [6] - ST Xuefa stated that it maintains independence from related parties, ensuring that external matters do not adversely affect its operations [7] - Lao Feng Xiang plans to establish a wholly-owned subsidiary in Hong Kong with a registered capital of 200 million USD for overseas investments [8] - Youzu Network indicated that its convertible bonds may trigger redemption conditions based on stock price performance [9] - Xintian Pharmaceutical received a cash dividend of 15 million yuan from its wholly-owned subsidiary, which will increase its net profit for the parent company but not affect consolidated net profit [11] - Xiehe Electronics announced that two shareholders plan to reduce their holdings by a total of up to 88,000 shares [13] - China Power Construction's subsidiary won a 10.77 billion yuan EPC contract for an offshore wind power project, although the contract is not yet signed [15]
共同药业(300966) - 2025年湖北辖区上市公司投资者网上集体接待日投资者关系活动记录表
2025-06-12 10:00
证券代码:300966证券简称:共同药业 湖北共同药业股份有限公司 2.系董事长您好:目前湖北共同甾体研究院已成立3年有余。 请问:该院承担的国家重点项目是什么,做了哪些创新药布局? 答:尊敬的投资者,您好,共同甾体研究院作为公司的研发平 台,依托高端科研团队,以突破菌种定向筛选、酶工程定向改造、 甾醇高效转化及绿色合成工艺四大核心技术,贯通"起始物料- 中间体-原料药"全链条,形成从基础研究到产业化转化的闭环创 新体系,技术成果获国家科技进步奖等多项权威认证,为公司打 造更稳固的核心竞争力。感谢您的关注,谢谢! 3.请问系董事长:公司创新药的布局,氟维司群研发进展? 答:尊敬的投资者,您好,感谢您的关注,具体产品信息以公 司指定的信息披露网站信披为准,谢谢! 4.公司销往国外的产品占比有多少?海外市场的开拓有哪些 规划? 答:尊敬的投资者,您好,2024年公司产品外销占比为28.54%, 近年来外销占比逐年上升;2025年公司将继续坚持国际化发展的 战略地位,在现有的基础上,不断拓展海外市场,一方面借助在 海外成立子公司的契机,加强公司在海外的品牌推广,增加销售 渠道;另一方面通过海外资源寻求商业合作,感谢 ...
贵州三力:股东海南悦欣计划减持公司股份不超过约205万股
Mei Ri Jing Ji Xin Wen· 2025-06-11 15:39
贵州三力(SH 603439,收盘价:12.34元)6月11日晚间发布公告称,截至本报告披露日,贵州三力制 药股份有限公司持股5%以上股东海南悦欣医药投资合伙企业(普通合伙)持有公司股份2100万股,占 公司总股本的约5.12%;公司副董事长、总经理、董事会秘书张千帆持有公司股份约71万股,占公司总 股本的0.1744%;公司董事、副总经理王毅持有公司股份约134万股,占公司总股本的0.3258%;公司副 总经理余渊持有公司股份约32万股,占公司总股本的0.0793%;公司副总经理罗战彪持有公司股份37万 股,占公司总股本的0.0903%。持股5%以上股东海南悦欣医药投资合伙企业(普通合伙)因自身业务需 求,拟从2025年7月3日至2025年10月2日期间,通过集中竞价交易方式减持其所持有的公司股份合计不 超过约205万股。公司副董事长、总经理、董事会秘书张千帆因个人资金需求,拟从2025年7月3日至 2025年10月2日期间,通过集中竞价交易方式减持其所持有的公司股份合计不超过约18万股。公司董 事、副总经理王毅因个人资金需求,拟从2025年7月3日至2025年10月2日期间,通过集中竞价交易方式 减持其所 ...
*ST苏吴(600200)6月11日主力资金净流出2294.66万元
Sou Hu Cai Jing· 2025-06-11 11:18
通过天眼查大数据分析,江苏吴中医药发展股份有限公司共对外投资了12家企业,参与招投标项目5 次,知识产权方面有商标信息47条,专利信息2条,此外企业还拥有行政许可9个。 资金流向方面,今日主力资金净流出2294.66万元,占比成交额19.03%。其中,超大单净流出796.05万 元、占成交额6.6%,大单净流出1498.61万元、占成交额12.43%,中单净流出流入480.73万元、占成交 额3.99%,小单净流入1813.93万元、占成交额15.04%。 来源:金融界 金融界消息 截至2025年6月11日收盘,*ST苏吴(600200)报收于2.63元,下跌1.13%,换手率6.41%, 成交量45.58万手,成交金额1.21亿元。 天眼查商业履历信息显示,江苏吴中医药发展股份有限公司,成立于1994年,位于苏州市,是一家以从 事医药制造业为主的企业。企业注册资本71215.1832万人民币,实缴资本12279.5762万人民币。公司法 定代表人为钱群山。 *ST苏吴最新一期业绩显示,截至2025一季报,公司营业总收入3.17亿元、同比减少25.44%,归属净利 润7031.79万元,同比减少1489.93 ...
信达国际控股港股晨报-20250611
Xin Da Guo Ji Kong Gu· 2025-06-11 03:14
Market Overview - The Hang Seng Index is testing the March high of 24,874 points, supported by a basket of financial policies from mainland China aimed at stabilizing the market, including reserve requirement ratio cuts and interest rate reductions [2] - The market is optimistic about the new round of negotiations in June, although trade war news remains volatile, and the Hang Seng Index's valuation has returned to reasonable levels, requiring significant positive developments in trade agreements and corporate earnings to maintain upward momentum [2][5] Macro Focus - The World Bank has significantly lowered its GDP forecast for the US this year to 1.4%, while maintaining China's forecast at 4.5% [3][7] - The US and China have reportedly reached a framework agreement during trade talks in Geneva, with further negotiations expected [7] Corporate News - Meituan's CFO stated that share buybacks will continue to be an important way to return value to shareholders amid concerns over the company's stock price performance [4][9] - Meituan's CEO emphasized that the commercialization of new technologies is still constrained by airspace limitations and public acceptance [9] - JD.com is reportedly expanding into the hotel and travel industry, actively recruiting talent with experience from Meituan and other companies [9][10] Industry Insights - The pharmaceutical sector is seeing renewed collaboration between Chinese and American companies amid manageable geopolitical risks [6] - AI concept stocks are gaining attention with advancements in large model upgrades [6] - The energy sector is preparing for increased demand during the summer, while coal prices continue to decline [6] Investment Opportunities - The logistics technology sector is experiencing significant growth, with Cainiao reporting over 60% year-on-year growth in global customer numbers and expectations for overseas sales growth to surpass domestic sales [9] - The electric vehicle industry is witnessing major players like BYD and Geely standardizing payment terms with suppliers to enhance cash flow efficiency [10]